Efficacy and safety of lamivudine treatment in late pregnancy with high HBV DNA: a perspective for mother and infants

Kose Ş., Turken M., Devrim I., Taner C.

JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, cilt.5, sa.4, ss.303-306, 2011 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 5 Sayı: 4
  • Basım Tarihi: 2011
  • Doi Numarası: 10.3855/jidc.1398
  • Dergi Adı: JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.303-306
  • Anahtar Kelimeler: lamivudine, chronic hepatitis B infection, pregnancy, HEPATITIS-B-VIRUS, PREVENT PERINATAL TRANSMISSION, PHARMACOKINETICS, INFECTION, ANTIGEN, SERUM
  • Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

Introduction: Perinatal transmission - from mother to fetus - is one of the main transmission routes of chronic hepatitis B (CHB) infection. Lamivudine therapy has been reported to prevent the replication of hepatitis B virus (HBV) in pregnant women with a high viral load that can lead to perinatal transmission.